Design and characterization of mouse IgG1 and IgG2a bispecific antibodies for use in syngeneic models.
Animals
Antibodies, Bispecific
/ genetics
CD3 Complex
/ immunology
CHO Cells
Cloning, Molecular
Cricetulus
Disease Models, Animal
Immunoglobulin G
/ genetics
Mice
Protein Binding
Protein Conformation
Protein Engineering
/ methods
Rituximab
/ metabolism
T-Lymphocytes
/ immunology
Transplantation, Isogeneic
Mouse bispecific antibodies
T-cell engaging bispecific antibody
co-expression
electrostatic steering
inter-chain disulfide bond shifting
syngeneic mouse model
Journal
mAbs
ISSN: 1942-0870
Titre abrégé: MAbs
Pays: United States
ID NLM: 101479829
Informations de publication
Date de publication:
Historique:
entrez:
21
12
2019
pubmed:
21
12
2019
medline:
9
1
2021
Statut:
ppublish
Résumé
The development of antibody therapeutics relies on animal models that accurately recapitulate disease biology. Syngeneic mouse models are increasingly used with new molecules to capture the biology of complex cancers and disease states, and to provide insight into the role of the immune system. The establishment of syngeneic mouse models requires the ability to generate surrogate mouse counterparts to antibodies designed for humans. In the field of bispecific antibodies, there remains a dearth of technologies available to generate native IgG-like mouse bispecific antibodies. Thus, we engineered a simple co-expression system for one-step purification of intact mouse IgG1 and IgG2a bispecific antibodies from any antibody pair. We demonstrated proof of concept with CD3/CD20 bispecific antibodies, which highlighted both the quality and efficacy of materials generated by this technology.
Identifiants
pubmed: 31856660
doi: 10.1080/19420862.2019.1685350
pmc: PMC6927765
doi:
Substances chimiques
Antibodies, Bispecific
0
CD3 Complex
0
Immunoglobulin G
0
Rituximab
4F4X42SYQ6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1685350Commentaires et corrections
Type : ErratumIn
Références
Sci Transl Med. 2015 May 13;7(287):287ra70
pubmed: 25972002
J Mol Biol. 2012 Jul 13;420(3):204-19
pubmed: 22543237
Biophys J. 2000 Mar;78(3):1606-19
pubmed: 10692345
Blood. 2000 Mar 15;95(6):2098-103
pubmed: 10706880
J Biol Chem. 2010 Jun 18;285(25):19637-46
pubmed: 20400508
Nature. 1983 Oct 6-12;305(5934):537-40
pubmed: 6137772
Biochemistry. 1997 Feb 18;36(7):1581-97
pubmed: 9048542
Proc Natl Acad Sci U S A. 2011 Jul 5;108(27):11187-92
pubmed: 21690412
MAbs. 2015;7(2):377-89
pubmed: 25621507
Pharmacol Ther. 2018 May;185:122-134
pubmed: 29269044
J Immunol. 2008 Nov 1;181(9):6664-9
pubmed: 18941257
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):125-32
pubmed: 20124692
Sci Rep. 2017 May 30;7(1):2476
pubmed: 28559564
Protein Eng Des Sel. 2010 Apr;23(4):195-202
pubmed: 20299542
Nat Med. 2000 Apr;6(4):443-6
pubmed: 10742152
J Immunol. 1995 Aug 1;155(3):1544-55
pubmed: 7636216
Proc Natl Acad Sci U S A. 2008 Apr 22;105(16):6045-50
pubmed: 18420815
Sci Rep. 2015 Dec 11;5:17943
pubmed: 26659273
Acta Crystallogr D Biol Crystallogr. 2010 Apr;66(Pt 4):486-501
pubmed: 20383002
Mol Cancer Ther. 2019 Feb;18(2):312-322
pubmed: 30381448
Proc Natl Acad Sci U S A. 2013 Mar 26;110(13):5145-50
pubmed: 23479652
MAbs. 2013 Sep-Oct;5(5):646-54
pubmed: 23924797
Nat Biotechnol. 1998 Jul;16(7):677-81
pubmed: 9661204
Immunity. 2005 Jul;23(1):41-51
pubmed: 16039578
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):213-21
pubmed: 20124702
J Immunol. 1995 Jul 1;155(1):219-25
pubmed: 7602098
Proc Natl Acad Sci U S A. 1987 Mar;84(5):1374-8
pubmed: 2950524
MAbs. 2017 Feb/Mar;9(2):182-212
pubmed: 28071970
Nat Rev Drug Discov. 2019 Aug;18(8):585-608
pubmed: 31175342
Nat Methods. 2013 May;10(5):407-9
pubmed: 23524392